论文部分内容阅读
目的探讨口服驱砷剂2,3-二巯基-1-丙基磺酸钠(DMPS)对砷中毒患者尿砷排泄量及其种类的影响。方法用激发实验原理设计实验方案,盲法测定样品。高效液相色谱-氢化物发生-原子吸收光谱法(HPLC-HG-AAS)分离并测定尿中无机砷(iAs)、一甲基砷酸(MMA)和二甲基砷酸(DMA)3种形态砷的含量;尿液经消化后用氢化物发生-原子吸收光谱法(HG-AAS)测定尿中总砷。结果无论对照还是砷中毒患者,口服DMPS后尿中总砷、无机砷、MMA和DMA的排出量均显著增加(P<0.01)。服用DMPS后,2组尿中无机砷、MMA占尿总砷含量的百分比都较服药前明显增加(P<0.01),而DMA经尿的排出比例却明显下降(P<0.01)。DMPS促进经尿排泄有机砷类的能力在对照和砷中毒患者间差异无统计学意义(P>0.05),DMPS可使砷中毒患者比正常对照排出更多的无机砷(P<0.05)。结论 DMPS能够动员器官和组织中蓄积砷,增加经尿的排泄总量。所增加的尿砷排泄以无机砷和MMA为主。
Objective To investigate the effect of oral administration of arsenic trioxide (DMEM) on urinary arsenic excretion and its type in arsenic poisoning patients. Methods The experimental protocol was designed by using excitation experiment principle, and the samples were determined by blinding method. High performance liquid chromatography-hydride generation-atomic absorption spectrometry (HPLC-HG-AAS) was used to separate and determine three kinds of inorganic arsenic (iAs), monomethyl arsenic (MMA) and dimethyl arsenate (DMA) Morphology Arsenic content; Determination of urinary total arsenic in urine by hydride generation-atomic absorption spectrometry (HG-AAS) after digestion. Results The urinary total arsenic, inorganic arsenic, MMA and DMA excretion increased significantly (P <0.01) in both control and arsenic poisoning patients. After taking DMPS, the percentage of inorganic arsenic and MMA in urine of two groups increased significantly (P <0.01), while the proportion of DMA excreted by urine decreased significantly (P <0.01). There was no significant difference in the ability of DMPS to promote the excretion of organic arsenite by urine (P> 0.05). DMPS could excrete more inorganic arsenic than the normal control (P <0.05). Conclusion DMPS can mobilize arsenic in organs and tissues and increase total urinary excretion. Increased urine arsenic excretion of inorganic arsenic and MMA-based.